4D Molecular Therapeutics (FDMT) Net Cash Flow (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Net Cash Flow data on file, last reported at $12.2 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 177.46% year-over-year to $12.2 million in Q1 2026; TTM through Mar 2026 was -$61.0 million, a 57.04% increase from a year earlier, with the FY2025 full-year figure at -$89.1 million, up 10.7% from the prior year.
• Net Cash Flow for Q1 2026 stood at $12.2 million, up from $11.7 million in the prior quarter.
• Over the last five years, Net Cash Flow for FDMT reached as high as $157.7 million in Q2 2023 and fell as low as -$86.5 million in Q2 2024.
• Historically, Net Cash Flow has averaged -$4.7 million across 5 years, with a median of -$5.2 million in 2022.
• Across the five-year window, Net Cash Flow surged 859.1% in 2023 and plunged 1779.37% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$55.9 million in 2022, then jumped by 52.51% to -$26.6 million in 2023, then sank by 43.78% to -$38.2 million in 2024, then surged by 130.59% to $11.7 million in 2025, then gained by 4.8% to $12.2 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $12.2 million in Q1 2026, $11.7 million in Q4 2025, and -$28.6 million in Q3 2025.